Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

WHAT'S NEW

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Apr 3 2017

Full Issue

DEA's Failed Attempt To Hold Drugmaker Accountable For Opioid Crisis Shows Just How Difficult It Is

In 2011, the agency targeted Mallinckrodt Pharmaceuticals for its opioid distribution practices. But six years later, after four investigations that spanned five states, the government has taken no legal action against the company. Meanwhile, the White House drug czar details information about fentanyl to lawmakers, and states mull mandatory opioid education classes in public schools.

The Washington Post: This Company’s Drugs Helped Fuel Florida’s Opioid Crisis. But The Government Struggled To Hold Them Accountable.

To combat an escalating opioid epidemic, the Drug Enforcement Administration trained its sights in 2011 on Mallinckrodt Pharmaceuticals, one of the nation’s largest manufacturers of the highly addictive generic painkiller oxycodone. It was the first time the DEA had targeted a manufacturer of opioids for alleged violations of laws designed to prevent diversion of legal narcotics to the black market. And it would become the largest prescription-drug case the agency has pursued. (Bernstein and Higham, 4/2)

The Wall Street Journal: Drug Czar’s Letter To Congress Highlights Fentanyl Crisis

The potent opioid fentanyl, which is worsening a deadly U.S. drug epidemic, is pouring into the country from an array of sources and presenting law enforcement with complex challenges, according to new information from the nation’s drug czar. A detailed letter to U.S. House lawmakers, responding to a request from the Energy and Commerce Committee, laid out many details about how authorities believe traffickers are moving and selling fentanyl. The drug czar’s office acknowledged available data don’t capture the full scope of the fentanyl crisis, yet still underscore an overwhelming problem. (Kamp and Campo-Flores, 3/31)

The Washington Post: States Begin To Use Schools To Fight Opioid Abuse

Michigan lawmakers are considering requiring mandatory opioid abuse education in public schools as part of a package of bills aimed at combating the addiction and overdose epidemic in the state. The proposal is similar to action taken in Ohio to provide K-12 students with instruction on the dangers of prescription opioid use. If the bill passes, the program would be implemented by the 2018 school year by the Michigan Department of Education. ­Massachusetts, Pennsylvania and South Carolina are considering similar bills. (Wiltz, 4/1)

And in other news on the crisis —

The Fiscal Times: The Billion Dollar Drug For Opioid Victims Has A Problem: It’s Addictive

Maryland Gov. Larry Hogan’s executive order earlier this month, declaring the state’s opioid addiction crisis a state of emergency, is yet another example of the state’s leadership in addressing a crisis. In the realm of medical treatments, Maryland took bold action last year to reduce access to the opioid treatment drug, Suboxone, which has become a dangerous drug on the streets and in prisons. (Yarrow, 3/31)

Minnesota Public Radio: A Killer Opioid's Dark Pathway To Minnesota

Just two salt-sized specs of it can kill. It's 10,000 times more potent than morphine, and 2 milligrams of it can stop a one-ton elephant in its tracks. Now, carfentanil is being blamed for five overdose deaths in Minnesota. (Nelson and Crann, 3/31)

WBUR: Public Bathrooms Become Ground Zero In The Opioid Epidemic

A man named Eddie threads through the mid-afternoon crowd in Cambridge's Central Square. He's headed for a sandwich shop, the first stop on a tour of public bathrooms available for drug use. Eddie, whose last name we're not including because he uses illegal drugs, knows which restrooms on Mass. Ave. he can enter, on what terms, at what hours and for how long. (Bebinger, 4/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, June 24
  • Tuesday, June 23
  • Monday, June 22
  • Thursday, June 18
  • Wednesday, June 17
  • Tuesday, June 16
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF